MK
Nippon Shinyaku Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Viltepso (viltolarsen) | Duchenne Muscular Dystrophy (exon 53 amenable) | Approved |
| NS-089/NCNP-02 | Duchenne Muscular Dystrophy (exon 44 amenable) | Phase 3 |
| NS-080/NCNP-01 | Duchenne Muscular Dystrophy (exon 45 amenable) | Phase 1/2 |
| Fostamatinib (TAK-632/R788) | Immune Thrombocytopenia (ITP) | Approved |
| Miglustat (Brazaves) | Niemann-Pick disease type C | Approved |
| NS-0100 | Undisclosed Oncology | Preclinical |
| NS-0200 | Undisclosed Rare Disease | Preclinical |
Leadership Team at Nippon Shinyaku
SH
Shigeki Hirao
Representative Director and President (CEO)
YK
Yoshihiro Kato
Director and Senior Managing Executive Officer
TS
Takeshi Suda
Director and Senior Managing Executive Officer
KM
Kazuhiko Matsushita
Director and Senior Managing Executive Officer
HK
Hiroshi Kawaguchi
Director and Managing Executive Officer
YN
Yoshihisa Nakagawa
Director and Managing Executive Officer
YS
Yoshihiko Sano
Director
MS
Masahiko Shibayama
Director
YK
Yoshiko Kita
Director
YY
Yoshihiro Yoneda
Director